Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02959112
Other study ID # 2008
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 2016
Est. completion date June 2019

Study information

Verified date February 2020
Source Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This multicentre randomised controlled trial included patients aged >18 years with an indication for ERCP and naive major papilla. All patients received 100 mg of rectal indomethacin and 10 ml of either sterile water or a 1:10,000 epinephrine dilution. Patients were asked about PEP symptoms via telephone 24 hours and 7 days after the procedure.


Description:

This multicentre randomised placebo-controlled trial was conducted in two hospitals in Mexico: the National Institute of Medical Sciences and Nutrition "Salvador Zubirán" (INCMNSZ) in Mexico City, and Bernardette Hospital in Jalisco. The study was approved by both institutional review boards. All patients provided written informed consent.

All patients were given a dose of rectal indomethacin (100 mg) at the beginning of the ERCP. Depending on the experimental group, either 10 ml of sterile water or 10 ml of a 1:10,000 epinephrine dilution (0.1 mg/ml) was sprayed on the ampulla through a biliary balloon or a sphincterotome, avoiding any direct contact with the papilla during irrigation at the end of the procedure.

After the procedure, patients were monitored in the recovery room for 2 hours and then discharged. Symptoms of acute pancreatitis or any other complication were interrogated at baseline while in the recovery room, and then by telephone 24 hours and 7 days after the procedure. Serum levels of pancreatic enzymes were determined only if the patient developed abdominal pain after ERCP.


Recruitment information / eligibility

Status Terminated
Enrollment 548
Est. completion date June 2019
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Age 18 years or older

- Patient with an indication for endoscopic retrograde cholangiopancreatography

- Patient without prior endoscopic retrograde cholangiopancreatography

- Patient who accept contact by telephone

Exclusion Criteria:

- Previous sphincterotomy

- Allergy to epinephrine or indomethacin

- NSAIDs use in the prior week

- Pancreatic cancer located in the head

- Chronic pancreatitis

- Renal failure (Cr >1.4 mg / dl)

- Indication for endotracheal intubation independent of endoscopic retrograde cholangiopancreatography

- Biliodigestive derivation

- Pregnant patients

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Epinephrine

Other:
Sterile water

Drug:
Indomethacin Rectal Suppository


Locations

Country Name City State
Mexico Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Tlalpan

Sponsors (1)

Lead Sponsor Collaborator
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with pancreatitis after endoscopic retrograde cholangiopancreatography, used consensus definition Consensus definition for post endoscopic retrograde cholangiopancreatography pancreatitis is: (1) new or worsened abdominal pain, (2) new or prolongation of hospitalization for at least 2 days, and (3) serum amylase or lipase 3 times or more the upper limit of normal, measured more than 24 hours after the procedure 7 days
Secondary Risk factors associated with the development of pancreatitis after endoscopic retrograde cholangiopancreatography assessed by relative risk 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT03609944 - SpHincterotomy for Acute Recurrent Pancreatitis N/A
Recruiting NCT05572788 - Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts N/A
Completed NCT03642769 - Lactated Ringer's Versus Normal Saline for Acute Pancreatitis N/A
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT04570852 - Acute Pancreatitis Targets (APT) Study N/A
Recruiting NCT03686618 - Secretin for Acute Pancreatitis Phase 2
Not yet recruiting NCT03740685 - Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis
Not yet recruiting NCT04037449 - Transversus Abdominis Plane Block in the Analgesia of Acute Pancreatitis N/A
Completed NCT03342716 - Resolution of Organ Injury in Acute Pancreatitis - RESORP
Not yet recruiting NCT03342807 - Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis Phase 4
Recruiting NCT05381428 - Prophylaxis of Post-ERCP Acute Pancreatitis Phase 3
Active, not recruiting NCT05955235 - A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study
Recruiting NCT05160506 - Corticosteroids to Treat Pancreatitis Phase 2
Not yet recruiting NCT03082469 - Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal Phase 4
Completed NCT03672422 - Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
Completed NCT00490386 - Helicobacter Pylori and Acute Alcohol Induced Pancreatitis N/A
Completed NCT04188990 - Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition N/A
Active, not recruiting NCT04743323 - A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis
Completed NCT03829085 - Study of the Diet in Patients With the Diagnostic of Acute Pancreatitis N/A
Not yet recruiting NCT04760847 - Intermittent Fasting for Pancreatitis N/A